LAUSR

We have read, reviewed and appreciated the work performed by Xie et al regarding the integrated network pharmacology and experimental approaches in order to investigate the mechanisms of Stigmasterol, the active components of Sinomenium acutum used in arthritis treatment. 1 Based on their results, 5 main differentially expressed genes involved in osteoclast differentiation, the major mediators of bone destruction, including NCF4, NFKB1, CYBA, IL-1β and NCF1 were determined to be targeted by the through protein–protein interaction (PPI) network. Sinomenium acutum (Thumb.) Rehd. et Wils. (Menispermaceae, SA) was known as a Chinese herbal medicine with various active chemical components, mainly alkaloid sinomenine. 2 The pharmacological profile of this herb includes immunosuppression, rheumatoid arthritis relief, anti-inflammatory, and protection against by lipopolysaccharide (LPS) induced hepatitis. 2 The study and drug design revealed in this article were found interesting and worth to be discussed further. In this study, the target genes of Sinomenium acutum active components related to rheumatoid arthritis were screened by heatmap and volcano map of dataset in Batman-TCM website which then was imported into Cytoscape software. Here, a question could be raised that the in silico prediction should be confirmed